Advantages of including untargeted and targeted metabolomics into drug development and clinical trials
Supported by:
15 July 2021
Shares
- Like
- Digg
- Del
- Tumblr
- VKontakte
- Buffer
- Love This
- Odnoklassniki
- Meneame
- Blogger
- Amazon
- Yahoo Mail
- Gmail
- AOL
- Newsvine
- HackerNews
- Evernote
- MySpace
- Mail.ru
- Viadeo
- Line
- Comments
- Yummly
- SMS
- Viber
- Telegram
- Subscribe
- Skype
- Facebook Messenger
- Kakao
- LiveJournal
- Yammer
- Edgar
- Fintel
- Mix
- Instapaper
- Copy Link
Discover how metabolomics can support your biomarker strategy in drug development and clinical trials in this on-demand webinar.
Discover how metabolomics can support your biomarker strategy in drug development and clinical trials in this on-demand webinar.
Biomarkers increase the success rate of drug development. Indeed, biomarker-driven drug development can de-risk multimillion-dollar decisions about the mechanism of action, safety, dosage, timing, patient response and other factors critical to your molecule’s success. However, traditional biomarker discovery tools, such as genomics, transcriptomics and proteomics, stop short of a definitive representation of the clinical phenotype. The addition of metabolomics provides a functional readout of all upstream biological processes as well as environmental factors (eg, microbiome), increasing confidence in your decisions and the success rate of drug development.
Experts discuss the use and benefits of incorporating untargeted and targeted metabolomics into the drug development process. How will an understanding of related pathways and the underlying physiology help you?
Learning outcomes
Learn how metabolomics can enable biomarker-driven drug development and clinical trials by providing:
- better understanding of a drug’s mechanism of action (MoA)
- greater confidence in human translational models
- insights into off-target effects and target engagement
- identification of unique therapy responders versus non-responders in clinical trials
- highly customised targeted assays to monitor clinical response.
Speakers
Dr Stephanie Ham, Study Director, Metabolon, Inc.
Stephanie Ham is a Study Director on the commercial team at Metabolon. She received her BS in chemical engineering from Miami University and her PhD in biomedical engineering from The University of Akron and has been working with novel biotechnologies to answer biological questions across different research fields ever since. Stephanie has been with Metabolon since 2019 and works with biotechnology and pharmaceutical clients to design, interpret and understand the biological meaning behind their metabolomics studies.
Dr Lisa Ford, Associate Director, Clinical and Targeted Analysis, Metabolon, Inc.
Lisa Ford is the technical leader of the quantitative analysis team at Metabolon. She received her BS in chemistry from UCLA and her PhD in bio-organic chemistry from Duke University and has been doing bioanalytical chemistry ever since.
Lisa has been with Metabolon since 2011 where she focuses on method development and performance of novel LC-MS/MS based tests for endogenous metabolites within the Clinical and Targeted Analysis lab, as well as supervising the CAP/CLIA compliant diagnostic tests performed at Metabolon.